|
MediciNova shares crash after lead asthma drug fails IIb trial
FierceBiotech MediciNova's ($MNOV) shares crashed after the San Diego-based biotech said its Phase IIb study of an acute asthma drug failed to hit the primary endpoint. And while the CEO tried to put the data in context, offering reasons for optimism for a planned … MediciNova asthma drug fails trial; shares crash MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … |
View full post on asthma – Google News